Mitochondrial DNA mutation m.10680G > A is associated with Leber hereditary optic neuropathy in Chinese patients
- 4k Downloads
Leber hereditary optic neuropathy (LHON) is a mitochondrial disorder with gender biased and incomplete penetrance. The majority of LHON patients are caused by one of the three primary mutations (m.3460G > A, m.11778G > A and m.14484T > C). Rare pathogenic mutations have been occasionally reported in LHON patients.
We screened mutation m.10680G > A in the MT-ND4L gene in 774 Chinese patients with clinical features of LHON but lacked the three primary mutations by using allele specific PCR (AS-PCR). Patients with m.10680G > A were further determined entire mtDNA genome sequence.
The optimal AS-PCR could detect as low as 10% heteroplasmy of mutation m.10680G > A. Two patients (Le1263 and Le1330) were identified to harbor m.10680G > A. Analysis of the complete mtDNA sequences of the probands suggested that they belonged to haplogroups B4a1 and D6a1. There was no other potentially pathogenic mutation, except for a few private yet reported variants in the MT-ND1 and MT-ND5 genes, in the two lineages. A search in reported mtDNA genome data set (n = 9277; excluding Chinese LHON patients) identified no individual with m.10680G > A. Frequency of m.10680G > A in Chinese LHON patients analyzed in this study and our previous studies (3/784) was significantly higher than that of the general populations (0/9277) (P = 0.0005).
Taken together, we speculated that m.10680G > A may be a rare pathogenic mutation for LHON in Chinese. This mutation should be included in future clinical diagnosis.
KeywordsLHON mtDNA m.10680G > A Chinese Rare primary mutation
Leber hereditary optic neuropathy (LHON, MIM535000) is one of the most common mitochondrial disorders, which mainly leads to vision loss in young males [1, 2, 3]. Three primary mutations (m.3460G > A in the MT-ND1 gene, m.11778G > A in the MT-ND4 gene, and m.14484T > C in the MT-ND6 gene) accounted for the etiology of more than 95% LHON patients, whereas the remaining 5% cases was caused by rare mutations and/or unclear factors [1, 2, 3]. Up to now, there is a considerable long list for rare mutations for LHON (cf. http://www.mitomap.org). Most recently, m.3635G > A in the MT-ND1 gene was confirmed to be a rare primary mutation and had a multiple occurrence in Han Chinese and Russian LHON families [4, 5, 6, 7]. Clinical expression of primary LHON mutation was affected by many factors including mtDNA background/haplogroups [8, 9], nuclear genes [10, 11, 12] and environmental factors [2, 13]. Though more and more LHON risk factors have been identified, there are abundant suspected LHON patients without any reported pathogenic mtDNA mutations [14, 15].
In our recent study, we found mutation m.10680G > A in a suspected LHON family lacking any known primary mutation, and this family had a considerably high penetrance of disease (40%; ) compared with that of families with m.11778G > A (about 33.3%; ). Similarly, Yang et al. reported one Chinese LHON family with both m.10680G > A and primary mutation m.14484T > C which expressed complete penetrance. These two studies suggested that m.10680G > A played an active role in LHON and might be a "suspected" pathogenic LHON mutation. In order to investigate the frequency of m.10680G > A in Chinese patients with clinical LHON features but without any known mutations, we screened this mutation in 774 suspected LHON patients by using the allele specific PCR (AS-PCR). Our analysis of the complete mtDNA genomes of the probands with mutation m.10680G > A suggested that this mutation should be regarded as a rare pathogenic mutation for LHON in Chinese.
Materials and methods
The patients were physically evaluated and collected at the Pediatric and Genetic Clinic of the Eye Hospital, Zhongshan Ophthalmic Center and/or other local clinical centers. All patients were subjected to acute or sub-acute vision loss and lacked the three known LHON primary mutations. We have sequenced the mtDNA control region sequence and classified these patients with suspected LHON into respective haplogroup and found no haplogroup was associated with suspected LHON . Because we used up DNA samples for some patients during that study, only 774 out of 843 patients with suspected LHON  were analyzed here. All these 774 patients were confirmed to harbor none of the four LHON primary mutations (m.3460G > A, m.3635G > A, m.11778G > A, and m.14484T > C). Informed consents conforming to the tenets of the Declaration of Helsinki were obtained from each participant prior to the study. The institutional review boards of Zhongshan Ophthalmic Center and Kunming Institute of Zoology approved this study.
Detection of mutation m.10680G > A
Mutation m.10680G > A was genotyped by using the AS-PCR in 774 suspected LHON patients. The primer pair for AS-PCR (L10680A: 5'-AGTCTTTGCCGCCTGCGATA-3'/H10972: 5'-TCAGGTAGTTAGTATTAGGAG-3') was designed according to the strategy described in Bi et al.. Another primer pair L4887 (5'-TGACAAAAACTAGCCCCCATCT -3')/H5442 (5'-GCGATGAGTGTGGGGAGGAA-3') was used as the internal control for monitoring successful amplification during the AS-PCR. PCR was performed in a total volume of 20 μL containing 30 ng DNA, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 50 mM KCl, 0.5 units of TaKaRa rTaq, 175 μM of each dNTP, and 0.3 μM of each primer. The amplification condition for AS-PCR is composed of one denaturation cycle at 94°C for 3 min, 30 cycles of denaturation at 94°C for 20 s, annealing at 61°C for 20 s, and extension at 72°C for 30 s, and one final extension cycle at 72°C for 5 min. In order to evaluate the sensitivity of the AS-PCR in detecting the minimum level of heteroplasmic mutation m.10680G > A, five different concentrations of genomic DNA of patient Le1263 with m.10680G > A (1 ng, 2.5 ng, 5 ng, 10 ng, and 15 ng) was used for amplification. In addition, DNA samples from patient Le1263 and a healthy donor without m.10680G > A were mixed to achieve final proportions of mutant DNA of 5%, 10%, and 20%, and a total of 30 ng of mixed DNA was amplified. The sensitivity is defined to be the smallest percentage of mutant DNA that can be detected by the AS-PCR method. PCR products were separated on 1.5% agarose gel at 120 V for 30 min.
Analysis of the entire mtDNA genome for patients with m.10680G > A
The entire mitochondrial genomes of probands with m.10680G > A were amplified and sequenced by using primers and methods described in our previous study . Sequences were handled by the DNASTAR program (DNAS Inc, Madison, WI, USA). We classified each patient into accurate haplogroup relative to the updated East Asian mtDNA tree and PhyloTree [20, 21, 22]. The novelty of variants/mutations was defined according to the available guidelines described by Bandelt et al.. We presented mtDNA sequence variations in probands sequenced in this study, together with two reported LHON mtDNAs with m.10680G > A (family Le1107 reported by Zou et al. and LHON family reported by Yang et al.) in a mtDNA tree. This phylogenetic approach has been demonstrated to be powerful to recognize private variants and haplogroup-specific variants in each lineage . Evolutionary conservation analysis of m.10680G > A was performed by using the MitoTool (http://www.mitotool.org) .
To discern the frequency of m.10680G > A in reported mtDNAs across world, we collected 9277 complete (and/or incomplete) mtDNA sequences from PhyloTree (mtDNA Tree Build 12, 20 Jul 2011)  and the MitoTool data set  and excluded those data of Chinese LHON patients. The ten reported Chinese patients with suspected LHON in our recent study  were aggregated with the patients screened in this study. Two tailed Fisher Exact test was used to evaluate the difference of m.10680G > A frequency between Chinese patients with suspected LHON and the reported data. A P value less than 0.05 was considered as significant.
Optimization of the AS-PCR for detecting m.10680G > A
Clinical data and frequency of m.10680G > A in patients with suspected LHON
The overall frequency of m.10680G > A in Chinese patients with suspected LHON was considerably low (0.26% = 2/774), although this frequency was significantly higher than that of the complied mtDNA data set for world populations (0/9277) (P = 0.006). When we included ten suspected LHON patients with family history that were reported in our previous study , the total frequency increased to 0.38% (3/784) (compared to the complied mtDNA data, P = 0.0005). A web-based search and database search  showed that mutation m.10680G > A only occurred in Chinese LHON patients. The penetrance of LHON in family Le1330 was relatively high (6/14 = 42.9%), similar to the reported family Le1107 (8/20 = 40.0%) in our previous study . All these results suggest that the rare mtDNA mutation m.10680G > A participates in the pathogenesis of LHON in Chinese.
Multiple occurrence of m.10680G > A in different Chinese mtDNA lineages
Private mtDNA variants in two Chinese probands with m.10680G>A
Nucleotide variant (Amino acid change)
m.3548T > C (p.I81T)
m.2352T > C
m.13327A > G (p.T331A)
m.3745G > A (p.A147T)
Though over 95% LHON patients was affected by one of the three primary mutations, the etiological factor of the remaining 5% LHON patients was unclear [1, 2, 3]. Many sporadic cases without three primary mutations have been reported and mtDNA mutations identified in these lineages were considered as pathogenic, despite the fact that the exact pathogenicity remains to be proved by functional assays. The spectra of the LHON primary mutations showed remarkable difference between European patients and Chinese patients [8, 9, 28, 29, 30], we speculated that there might be some more pathogenic mtDNA mutations that were unique to Chinese LHON patients.
In this study, we designed an AS-PCR to detect mutation m.10680G > A in 774 Chinese patients with suspected LHON and found two patients harboring this mutation. Our approach had a reasonably good sensitivity in detecting minimum level of mutant DNA of 10% of total DNA template ≥ 10 ng). Compared to other approaches, such as sequencing, single-strand conformation polymorphism (SSCP), and restriction fragment length polymorphism (RFLP), the AS-PCR method is fast and cost-effective and can be of potential usage in the clinic for fast screening of mutation m.10680G > A in patients with suspected LHON. We did not identify any heteroplasmy of mutation m.10680G > A in the two patients with m.10680G > A in this study and patient Le1107 in our previous study  based on the limitation of detection sensitivity of our AS-PCR and direct sequencing approach. Though we did not design an allele-specific PCR (or a PCR-RFLP method) to detect the minimum level of wild-type allele in these patients to double check for heteroplasmy, the overall pattern was consistent with our previous observation for a very low frequency of heteroplasmic m.11778G > A (1/479 = 0.21%; Ref. ) and m.14484T > C (3/52 = 5.8%; Ref. ) in Han Chinese patients. As m.10680G > A creates a digestion site for enzyme Tse I, we could also use PCR-RFLP method to screen this mutation and measure the level of heteroplasmy. One limitation is that enzyme Tse I is quite expensive and this PCR-RFLP method is not cost-effective and time-consuming in clinic.
A web-based and database search showed that mutation m.10680G > A has been independently reported to affect LHON in two Chinese families [15, 16]. These two reported patients belonged to haplogroups M13a  and B4d  (Figure 3). Therefore, it seemed that mutation m.10680G > A occurred only in Chinese LHON patients and had a multiple occurrence in different mtDNA background. In the Chinese family reported by Yang et al., m.10680G > A coexisted with primary mutation m.14484T > C, and the presence of both mutations caused complete penetrance of LHON. In the two families with m.10680G > A reported in this study and our previous study , we found that the penetrance of LHON (> 40%) was even higher than those families with m.11778G > A (33.3%; Ref. ), m.14484T > C (31.9%; Ref. ) or m.3460G > A (25.6%; Ref. ). Patient Le1263 was self-reported as sporadic and his family was not considered to calculate the penetrance. Note that our estimation for disease penetrance for m.10680G > A was based on two families, which might lead to a bias.
Analysis for the entire mtDNA genomes of the two patients with m.10680G > A identified in this study showed that they harbored no novel or "confirmed" pathogenic mutation. However, variant m.3548T > C was found in patient Le1263, which is located in the mutational hotspot (MT-ND1 gene) for Chinese patients with LHON but lacking three known primary mutations  and was also reported in another LHON patient , whether m.3548T > C had a synergistic effect with m.10680G > A to influence disease expression in Le1263 was not clear, as we lacked necessary clinical information and this patient had no self-reported family history of disease. Similarly, two private variants were found in patient Le1330, which were located in the MT-ND1 and MT-ND5 genes (Table 1), further supported our previous claim that the MT-ND1 and MT-ND5 genes are mutational hotspots for Chinese families with clinical features of LHON but lacking the three primary mutations .
In summary, we designed an AS-PCR method for rapid screening of m.10680G > A in a large cohort of Chinese patients with suspected LHON and identified two Chinese subjects with m.10680G > A. Analysis of the complete mtDNA sequences of the two probands and combining with information of two reported cases [15, 16], we proposed that m.10680G > A is a rare pathogenic mutation in Chinese LHON population. Further functional assays, e.g. respiration measurements and NADH:ubichinon oxidoreductase activity assays in patient fibroblasts and eventually in newly constructed cybrid cell lines harbouring the mutation, should be carried out and more families with m.10680G > A should be included to validate our conclusion.
We thank patients for participating in this study and the two anonymous reviewers for helpful comments on the early version of the manuscript. This work was supported by the National Natural Science Foundation of China (30925021), Yunnan Province (2009CI119) and Guangdong Province (2009B091300150).
- 8.Ji Y, Zhang A-M, Jia X, Zhang Y-P, Xiao X, Li S, Guo X, Bandelt H-J, Zhang Q, Yao Y-G: Mitochondrial DNA haplogroups M7b1'2 and M8a affect clinical expression of leber hereditary optic neuropathy in Chinese families with the m.11778 G > A mutation. Am J Hum Genet. 2008, 83: 760-768. 10.1016/j.ajhg.2008.11.002.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Hudson G, Carelli V, Spruijt L, Gerards M, Mowbray C, Achilli A, Pyle A, Elson J, Howell N, La Morgia C: Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background. Am J Hum Genet. 2007, 81: 228-233. 10.1086/519394.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Phasukkijwatana N, Kunhapan B, Stankovich J, Chuenkongkaew WL, Thomson R, Thornton T, Bahlo M, Mushiroda T, Nakamura Y, Mahasirimongkol S: Genome-wide linkage scan and association study of PARL to the expression of LHON families in Thailand. Hum Genet. 2010, 128: 39-49. 10.1007/s00439-010-0821-8.CrossRefPubMedGoogle Scholar
- 14.Ferré M, Bonneau D, Milea D, Chevrollier A, Verny C, Dollfus H, Ayuso C, Defoort S, Vignal C, Zanlonghi X: Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 novel OPA1 mutations. Hum Mutat. 2009, 30: E692-705. 10.1002/humu.21025.CrossRefPubMedGoogle Scholar
- 15.Zou Y, Jia X, Zhang A-M, Wang W-Z, Li S, Guo X, Kong Q-P, Zhang Q, Yao Y-G: The MT-ND1 and MT-ND5 genes are mutational hotspots for Chinese families with clinical features of LHON but lacking the three primary mutations. Biochem Biophys Res Commun. 2010, 399: 179-185. 10.1016/j.bbrc.2010.07.051.CrossRefPubMedGoogle Scholar
- 19.Wang H-W, Jia X, Ji Y, Kong Q-P, Zhang Q, Yao Y-G, Zhang Y-P: Strikingly different penetrance of LHON in two Chinese families with primary mutation G11778A is independent of mtDNA haplogroup background and secondary mutation G13708A. Mutat Res. 2008, 643: 48-53. 10.1016/j.mrfmmm.2008.06.004.CrossRefPubMedGoogle Scholar
- 20.Kong Q-P, Sun C, Wang H-W, Zhao M, Wang W-Z, Zhong L, Hao X-D, Pan H, Wang S-Y, Cheng Y-T: Large-scale mtDNA screening reveals a surprising matrilineal complexity in East Asia and its implications to the peopling of the region. Mol Biol Evol. 2011, 28: 513-522. 10.1093/molbev/msq219.CrossRefPubMedGoogle Scholar
- 26.Crispim D, Estivalet AA, Roisenberg I, Gross JL, Canani LH: Prevalence of 15 mitochondrial DNA mutations among type 2 diabetic patients with or without clinical characteristics of maternally inherited diabetes and deafness. Arq Bras Endocrinol Metabol. 2008, 52: 1228-1235. 10.1590/S0004-27302008000800005.CrossRefPubMedGoogle Scholar
- 31.Kervinen M, Patsi J, Finel M, Hassinen IE: A pair of membrane-embedded acidic residues in the NuoK subunit of Escherichia coli NDH-1, a counterpart of the ND4L subunit of the mitochondrial complex I, are required for high ubiquinone reductase activity. Biochemistry. 2004, 43: 773-781. 10.1021/bi0355903.CrossRefPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.